Data Insights

Abexinostat by Xynomic Pharmaceuticals for Follicular Lymphoma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase II for Follicular Lymphoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Follicular Lymphoma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for High-Grade Glioma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for High-Grade Glioma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in High-Grade Glioma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Oligodendroglioma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Oligodendroglioma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Oligodendroglioma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Gliosarcoma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Gliosarcoma. According to GlobalData, Phase I...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Gliosarcoma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Anaplastic Astrocytoma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Anaplastic Astrocytoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Anaplastic Astrocytoma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Glioblastoma Multiforme (GBM): Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Glioblastoma Multiforme (GBM). According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Glioblastoma Multiforme (GBM)

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Non-Small Cell Lung Cancer: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Non-Small Cell Lung Cancer. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Non-Small Cell Lung Cancer

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Merkel Cell Carcinoma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Merkel Cell Carcinoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Merkel Cell Carcinoma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Head And Neck Squamous Cell Carcinoma (HNSC): Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Head And Neck Squamous Cell Carcinoma...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Head And Neck Squamous Cell Carcinoma (HNSC)

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Metastatic Transitional (Urothelial) Tract Cancer: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Metastatic Transitional (Urothelial) Tract Cancer. According...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Metastatic Transitional (Urothelial) Tract Cancer

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Thymic Carcinoma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Thymic Carcinoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Thymic Carcinoma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Adenocarcinoma Of The Gastroesophageal Junction: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Adenocarcinoma Of The Gastroesophageal Junction. According...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Adenocarcinoma Of The Gastroesophageal Junction

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Malignant Mesothelioma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Malignant Mesothelioma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Malignant Mesothelioma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Metastatic Melanoma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Metastatic Melanoma. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Metastatic Melanoma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Small-Cell Lung Cancer: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase I for Small-Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Small-Cell Lung Cancer

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Mantle Cell Lymphoma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase II for Mantle Cell Lymphoma. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Mantle Cell Lymphoma

Data Insights

Abexinostat by Xynomic Pharmaceuticals for Diffuse Large B-Cell Lymphoma: Likelihood of Approval

Abexinostat is under clinical development by Xynomic Pharmaceuticals and currently in Phase II for Diffuse Large B-Cell Lymphoma. According to...

Likelihood of Approval and Phase Transition Success Rate Model - Abexinostat in Diffuse Large B-Cell Lymphoma